The Current Ratio as of November 2024 (TTM) for Zai Lab Limited (ZLAB) is 3.46

According to Zai Lab Limited’s latest financial reports and current stock price. The company's current Current Ratio is 3.46. This represents a change of -32.21% compared to the average of 5.10 of the last 4 quarters.

Zai Lab Limited (ZLAB) Historical Current Ratio (quarterly & annually)

How has ZLAB Current Ratio performed in the past?

The mean historical Current Ratio of Zai Lab Limited over the last ten years is 9.26. The current 3.46 Current Ratio has changed 3.63% with respect to the historical average. Over the past ten years (40 quarters), ZLAB's Current Ratio was at its highest in in the September 2017 quarter at 19.11. The Current Ratio was at its lowest in in the March 2016 quarter at 0.

Zai Lab Limited (ZLAB) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Zai Lab Limited Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Zai Lab Limited (ZLAB) Average Current Ratio

How has ZLAB Current Ratio performed in the past?

The current Current Ratio of Zai Lab Limited (ZLAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Zai Lab Limited (ZLAB) Current Ratio vs. Peers

How is ZLAB’s Current Ratio compared to its peers?

Zai Lab Limited’s Current Ratio is less than C4 Therapeutics, Inc. (6.31), less than Erasca, Inc. (16.79), less than Cullinan Oncology, Inc. (28.87), less than Legend Biotech Corporation (4.84), greater than Seagen Inc. (2.67), greater than Alnylam Pharmaceuticals, Inc. (2.75), greater than Ascendis Pharma A/S (0.74), less than Roivant Sciences Ltd. (0), less than Krystal Biotech, Inc. (27.91), less than Prometheus Biosciences, Inc. (9.50), less than Akero Therapeutics, Inc. (37.56), less than Apellis Pharmaceuticals, Inc. (24.89), less than PTC Therapeutics, Inc. (5.08), greater than Blueprint Medicines Corporation (2.23), greater than Intercept Pharmaceuticals, Inc. (3.32), less than Madrigal Pharmaceuticals, Inc. (4.22), less than null (5.98),

Build a custom stock screener for Zai Lab Limited (ZLAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zai Lab Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Zai Lab Limited (ZLAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Zai Lab Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.